Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Saniona

11.23 SEK+0.36 %20/11 17:29
Less than 1K followers

SANION

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.36 %
+6.34 %
-10.59 %
-17.49 %
-47.03 %
-34.63 %
+100.49 %
+15.81 %
+186.75 %

Saniona is a biotechnology company focused on developing treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.

Read more
Market cap
1.55B SEK
Turnover
2.9M SEK
Revenue
434.4M
EBIT %
62.39 %
P/E
5.08
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

Press release2026-11-20 08:00

Saniona appoints Carrie Cook as Chief Business Officer

Saniona
Press release2026-11-20 08:00

Saniona utser Carrie Cook till Chief Business Officer

Saniona
Press release2026-11-19 08:00

Invitation to Saniona Q3 investor call on 26 November 2026

Saniona

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-11-19 08:00

Inbjudan till Sanionas investerarsamtal för Q3 den 26 november 2026

Saniona
Press release2026-11-17 13:17

Redeye: Saniona: FDA clears SAN2465 for Phase I

Saniona
Press release2026-11-16 08:00

Saniona receives FDA clearance to initiate Phase 1 of SAN2465

Saniona
Press release2026-11-16 08:00

Saniona får FDA-godkännande att inleda fas 1-studie med SAN2465

Saniona
Press release2026-11-13 08:00

Saniona receives positive EU orphan drug designation opinion for SAN2668 in CHD2-related neurodevelopmental disorder

Saniona
Press release2026-11-13 08:00

Saniona får positivt yttrande om särläkemedelsstatus i EU för SAN2668 vid CHD2-relaterad neurologisk utvecklingsstörning

Saniona
Press release2026-11-10 08:00

Saniona sells AstronauTx shareholding for GBP 3.36 million (SEK 44.5 million)

Saniona
Press release2026-11-10 08:00

Saniona säljer innehavet i AstronauTx för 3,36 miljoner GBP (44,5 MSEK)

Saniona
Press release2026-11-06 08:00

Saniona successfully completes Phase 1-enabling work for SAN2668

Saniona
Press release2026-11-06 08:00

Saniona slutför framgångsrikt arbetet inför fas 1 med SAN2668

Saniona
Press release2026-11-03 08:00

Saniona AB:s valberedning inför årsstämman 2027

Saniona
Press release2026-11-03 08:00

Saniona AB’s Nomination Committee for the Annual General Meeting 2027

Saniona
Regulatory press release2026-11-02 12:00

Bulletin from the Saniona AB extraordinary shareholders’ meeting on November 2, 2026

Saniona
Regulatory press release2026-11-02 12:00

Kommuniké från extra bolagsstämma den 2 november 2026 i Saniona AB

Saniona
Press release2026-10-20 08:00

Saniona submits IND application for SAN2465 for major depressive disorder

Saniona
Press release2026-10-20 08:00

Saniona lämnar in IND-ansökan för SAN2465 för behandling av svår depression

Saniona
Press release2026-10-13 08:00

Saniona announces new preclinical data reinforcing SAN2465’s potential as a rapid-acting antidepressant

Saniona